What is Selank?

• What Selank is and how it was built from the immunopeptide tuftsin
• Its multimodal mechanism: GABA modulation, enkephalinase inhibition, serotonin, and BDNF
• What the Russian clinical trials showed, and why the English-language evidence is thin
• Its regulatory reality: registered in Russia, not approved in the US, and the 503A saga

1. 01 What is Selank? A Russian anxiety peptide built from an immune molecule free
2. 02 The tuftsin origin story From a 1970 immune discovery to a Moscow anxiety peptide paid
3. 03 How it calms: GABA & enkephalin Calming the brain without hijacking it paid
4. 04 BDNF, serotonin & cognition Beyond calm: growth factors and mood chemistry paid
5. 05 The immune inheritance What Selank kept from its immune ancestor paid
6. 06 The clinical evidence A real clinical record, in the wrong language paid
7. 07 Chemistry & nose-to-brain delivery Seven residues, three prolines, and a path to the brain paid
8. 08 Safety & Side Effects A gentle profile, honestly qualified paid
9. 09 Dosing & Administration What the label says, and what it cannot tell you paid
10. 10 Regulatory landscape One molecule, a patchwork of legal realities paid
11. 11 Final Exam & Certification Pass the final exam to earn your certificate of completion. Exam

Selank is a redesigned immune peptide. Chemists at the Institute of Molecular Genetics in Moscow, working with the Zakusov Research Institute of Pharmacology, started with tuftsin (Thr-Lys-Pro-Arg), a natural four-amino-acid piece of an antibody chain that stimulates phagocytes, the immune cells that engulf invaders, and extended it with a small protective tail. The result is the seven-amino-acid peptide Thr-Lys-Pro-Arg-Pro-Gly-Pro, registered in Russia as nasal drops for anxiety.

The key idea is that a tiny structural change unlocked a very different use. Tuftsin is an immune stimulant; its designers added the Pro-Gly-Pro tail, in their own words, to enhance metabolic stability and the length of action, and the emphasis shifted toward the brain and stress systems. How short-lived native tuftsin actually is was not measured in any source cited here, so treat the stability gain as a stated design goal rather than a measured one.

The most common misconception is that Selank is "a benzodiazepine you can't get addicted to." That is wrong. Benzodiazepines act on the brain's GABA-A receptors and enhance GABA's effect by allosteric modulation, which makes the receptor's chloride channel open more often; sedation, muscle relaxation, tolerance and withdrawal are among their typical side effects. Radioligand work describes Selank as a positive allosteric modulator of [3H]GABA binding too, so the difference is not "allosteric versus direct". It is where and how: its authors judge Selank's binding site apparently not the same as the benzodiazepine site, though possibly partly overlapping, and Selank also changes the expression of GABA-related genes and inhibits enkephalin-degrading enzymes.

This distinction matters for expectations and safety. Sedation is part of a benzodiazepine's typical side-effect profile; Selank is described as tuning the same system more gently, through an apparently different site, gene expression, and the body's own enkephalins. That is the honest basis for the "no-benzo profile" claim, though as later units show, it has not been proven in modern Western trials.

Selank does not have a single known mechanism. Its papers describe effects on several stress- and mood-relevant systems at once, which is why this course teaches it as several modest levers rather than one strong one. Seeing all the pillars together up front makes the rest of the course easier to follow, since each later unit zooms into one of them.

No single pillar is the whole answer, and that is the point. A benzodiazepine has one dominant mechanism; Selank spreads its effect across five weaker levers. That breadth may explain both its gentle, non-sedating feel and the difficulty of pinning down exactly how it works, a recurring theme when the evidence gets examined honestly.

Selank's legal status is genuinely split by geography. In Russia it is a registered medicine with a defined use, nasal drops for anxiety states; in the United States no FDA-approved label carries its name, and a search of DailyMed, the national labelling database, returns no record for it. Understanding this divide is essential before reading any claim about its safety or effectiveness.

This is not a technicality. In Russia, a patient gets a registered product with a defined dose and indication and a manufacturer answerable for it. In the US there is no approved product to compare it with, so nothing stands behind whatever someone obtains instead. The same molecule can be a regulated medicine or an unregulated unknown depending on where you are.

Selank sits in an unusual evidence position: stronger than internet hype, weaker than an FDA-approved drug. Its mechanism has real English-language studies, its anxiety trials were published in Russian journals and are indexed in English only as abstracts, and in the US no FDA-approved label carries its name. This course keeps those tiers strictly separate instead of blurring them into marketing.

Keep these tiers in mind for the whole course. The mechanism story is worth taking seriously, the Russian clinical record is real but published in Russian and indexed in English only as abstracts, and ClinicalTrials.gov lists no trial of Selank. Honest education names that structure plainly rather than rounding Selank up to "proven" or down to "snake oil."